Skip to main content
European Commission logo print header

Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration

Obiettivo

Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration

This feasibility study is to verify the technical and economic viability of a sustained release bevacizumab product (SR Bevacizumab) to improve the safety, cost-effectiveness and patient acceptability for the treatment of wet age-related macular degeneration (AMD). AMD is the leading cause of blindness in those aged over 50 and causes blurring, distortion and loss of central vision and almost always affects quality of life. Prototype SR Bevacizumab products will be manufactured using CriticalMix, an advanced manufacturing and processing technology developed by Critical Pharmaceuticals, which will encapsulate bevacizumab in biodegradable polymers suitable for sustained release of the drug in the eye.

Invito a presentare proposte

H2020-SMEInst-2014-2015

Vedi altri progetti per questo bando

Bando secondario

H2020-SMEINST-1-2014

Meccanismo di finanziamento

SME-1 - SME instrument phase 1

Coordinatore

CRITICAL PHARMACEUTICALS LIMITED
Contribution nette de l'UE
€ 50 000,00
Indirizzo
BIOCITY NOTTINGHAM - PENNYFOOT STREET
NG1 1GF NOTTINGHAM
Regno Unito

Mostra sulla mappa

PMI

L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.

Regione
East Midlands (England) Derbyshire and Nottinghamshire Nottingham
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 71 429,00